Expression of PIK3CA-mutants in EGFRM+ NSCLC cell lines makes them resistant to EGFR-TKIs by activating AKT-signaling and inhibiting TKI-induced apoptosis [39]. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.